2025 Hereditary Angioedema Association (HAEA) US Summit Congress

BioCryst will attend the 2025 Hereditary Angioedema Association (HAEA) US Summit Congress from July 10-13, 2025.

  • Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results From APeX-P
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results From a Focus Group
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Impact of Berotralstat on Quality of Life in Patients with Hereditary Angioedema
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Berotralstat for the Prevention of Hereditary Angioedema Attacks: Results from the Italian Expanded Access Programme
    C1-INH Def Wkshp | 2025 | Hereditary Angioedema (HAE)

Have questions about any of our medicines that are currently approved or in development, or would you like to request to be connected with an MSL?

Have questions about our company?